Future of Stem-Cell Tests Hangs On Definition of Embryo Harm

This article is from the archive of The New York Sun before the launch of its new website in 2022. The Sun has neither altered nor updated such articles but will seek to correct any errors, mis-categorizations or other problems introduced during transfer.

The New York Sun

WASHINGTON — With the active encouragement of the Bush administration, American scientists in the past year have developed several methods for creating embryonic stem cells without having to destroy human embryos.

But some who now wish to test their alternatively derived cells have found themselves stymied by an unexpected barrier: President Bush’s stem-cell policy.

The 2001 policy says that federal funds may not be used to study embryonic stem cells created after August 9 of that year. It is based on the assumption that the only way to make the cells is by destroying human embryos — a truism in 2001 but not any longer.

As a result, the National Institutes of Health recently refused to consider a grant application for what would have been the first federal study to compare several of the new, less politically contentious stem-cell lines.

“This is not the way to make good health policy,” said Robert Lanza, the frustrated vice president for research and scientific development at Advanced Cell Technology in Worcester, Mass. Mr. Lanza submitted the study proposal with stem-cell experts from several major research labs.

Upcoming changes in the NIH’s stem-cell funding rules may eventually help resolve that problem. But agency officials and others say the policy tangle is more complicated than that. Although Mr. Lanza’s technique and other new approaches do not destroy embryos, they may run afoul of a long-standing congressional ban on studies that “harm” human embryos.

That vague language raises the perplexing question of how one would know whether an embryo had been harmed. At the center of the debate is a new technique, pioneered by ACT, that obtains stem cells from human embryos while leaving the embryos functionally intact. A single cell, called a blastomere, is removed from an eight-cell human embryo, then coaxed to multiply into a colony of stem cells in a dish.

Fertility doctors have been performing these blastomere biopsies for years to identify embryos that harbor genetic defects. Since a single cell is representative of the entire embryo, doctors transfer to a mother-to-be’s womb only those embryos whose plucked cells pass genetic muster. The loss of a single cell — or even two — at that stage is not known to cause developmental problems in children born by this procedure, doctors say.

In unpublished research, ACT has made several colonies of stem cells this way, Mr. Lanza said. The seven-cell embryos developed normally and were frozen after the procedure a couple of days later, as embryos typically are until used by infertile couples.

The question is whether stem cells made this way are as versatile as those harvested from destroyed embryos. And what about stem cells created by other means, such as those of Anthony Atala, the Wake Forest University scientist who in January announced he had isolated embryonic stem cell equivalents from amniotic fluid? To find out, Mr. Lanza joined with Mr. Atala and a team of others to compare stem cells made by various means. The group submitted a proposal to the NIH in February, then waited. And waited.

Eventually, the NIH told the team that it had referred the proposal to a different review group. Then, in a series of e-mails, the agency backed off further, first encouraging the applicants to drop Mr. Lanza’s cells from the proposal and, finally, when the team refused to do so, informing them that the application was being sidelined indefinitely for “administrative review.”

Story Landis, who heads the NIH’s stem-cell task force, said the main issue is Mr. Bush’s August 9, 2001, stem-cell policy. It called upon the NIH to make a list of all embryonic stem-cell lines known as of that date and blocked funding for research on any cells but those on the list. “Currently, there are no cell lines derived from single blastomeres listed on the stem-cell registry as eligible for funding,” Mr. Landis said.

Sean Tipton, president of the Coalition for the Advancement of Medical Research, a stem cell research advocacy group, said the policy amounts to a Catch-22.

“On the one hand, they’re saying, ‘Find this out,'” Mr. Tipton said, referring to the White House’s call for scientists to find ways to make and study stem cells without destroying embryos. “On the other hand, they’re saying, ‘You’re not allowed to do the research to answer these questions.'”


The New York Sun

© 2024 The New York Sun Company, LLC. All rights reserved.

Use of this site constitutes acceptance of our Terms of Use and Privacy Policy. The material on this site is protected by copyright law and may not be reproduced, distributed, transmitted, cached or otherwise used.

The New York Sun

Sign in or  create a free account

By continuing you agree to our Privacy Policy and Terms of Use